"Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "11"^^ . "58" . . "I" . . "Chronic myeloid leukemia: a crucial change to the patient prognosis after an introduction of tyrosine kinase inhibitors"@en . "127148" . . . . . . . "Klamov\u00E1, Hana" . "0042-773X" . . "Chronick\u00E1 myeloidn\u00ED leukemie: z\u00E1sadn\u00ED zm\u011Bna progn\u00F3zy nemocn\u00FDch po zaveden\u00ED l\u00E9\u010Dby inhibitory tyrozinov\u00FDch kin\u00E1z" . "http://www.prolekare.cz/vnitrni-lekarstvi-clanek/chronicka-myeloidni-leukemie-zasadni-zmena-prognozy-nemocnych-po-zavedeni-lecby-inhibitory-tyrozinovych-kinaz-38871" . . "Chronick\u00E1 myeloidn\u00ED leukemie: z\u00E1sadn\u00ED zm\u011Bna progn\u00F3zy nemocn\u00FDch po zaveden\u00ED l\u00E9\u010Dby inhibitory tyrozinov\u00FDch kin\u00E1z" . "Chronick\u00E1 myeloidn\u00ED leukemie (CML) je p\u0159\u00EDkladem onemocn\u011Bn\u00ED, kde nov\u00E9 poznatky v molekul\u00E1rn\u00ED biologii umo\u017Enily nejen d\u016Fkladn\u00E9 pozn\u00E1n\u00ED podstaty nemoci, ale vedly tak\u00E9 k objevu zcela nov\u00E9ho, c\u00EDlen\u00E9ho principu l\u00E9\u010Dby a to inhibic\u00ED tyrozinov\u00E9 kin\u00E1zy Bcr-Abl, kter\u00E1 se stala hlavn\u00EDm terapeutick\u00FDm c\u00EDlem. Onemocn\u011Bn\u00ED s p\u016Fvodn\u011B fat\u00E1ln\u00ED progn\u00F3zou se zm\u011Bnilo u pacient\u016F diagnostikovan\u00FDch v chronick\u00E9 f\u00E1zi nemoci v onemocn\u011Bn\u00ED s o\u010Dek\u00E1van\u00FDm medi\u00E1nem p\u0159e\u017Eit\u00ED odhadovan\u00FDm na v\u00EDce ne\u017E 25 let." . . "CZ - \u010Cesk\u00E1 republika" . . . "Chronick\u00E1 myeloidn\u00ED leukemie: z\u00E1sadn\u00ED zm\u011Bna progn\u00F3zy nemocn\u00FDch po zaveden\u00ED l\u00E9\u010Dby inhibitory tyrozinov\u00FDch kin\u00E1z"@cs . "Chronick\u00E1 myeloidn\u00ED leukemie (CML) je p\u0159\u00EDkladem onemocn\u011Bn\u00ED, kde nov\u00E9 poznatky v molekul\u00E1rn\u00ED biologii umo\u017Enily nejen d\u016Fkladn\u00E9 pozn\u00E1n\u00ED podstaty nemoci, ale vedly tak\u00E9 k objevu zcela nov\u00E9ho, c\u00EDlen\u00E9ho principu l\u00E9\u010Dby a to inhibic\u00ED tyrozinov\u00E9 kin\u00E1zy Bcr-Abl, kter\u00E1 se stala hlavn\u00EDm terapeutick\u00FDm c\u00EDlem. Onemocn\u011Bn\u00ED s p\u016Fvodn\u011B fat\u00E1ln\u00ED progn\u00F3zou se zm\u011Bnilo u pacient\u016F diagnostikovan\u00FDch v chronick\u00E9 f\u00E1zi nemoci v onemocn\u011Bn\u00ED s o\u010Dek\u00E1van\u00FDm medi\u00E1nem p\u0159e\u017Eit\u00ED odhadovan\u00FDm na v\u00EDce ne\u017E 25 let."@cs . "RIV/00023736:_____/12:00009808!RIV13-MZ0-00023736" . . "1"^^ . "S2" . "Chronic myeloid leukemia: a crucial change to the patient prognosis after an introduction of tyrosine kinase inhibitors"@en . . "[CF8CA5025725]" . . . "RIV/00023736:_____/12:00009808" . "Chronic myeloid leukemia (CML) is an example of a disease where new knowledge in molecular biology enabled thorough understanding of the nature of the disease as well as it led to a discovery of completely new, targeted treatment principle, i.e. inhibition of tyrosine kinase Bcr-Abl, now the main therapeutic target. A disease with originally fatal prognosis has changed in patients diagnosed in its chronic phase to a disease with expected median of survival estimated at more than 25 years."@en . "chronic myeloid leukemia; tyrosine kinase inhibitors; Imatinib; dasatinib; nilotinib; interferon alpha"@en . "1"^^ . . "Chronick\u00E1 myeloidn\u00ED leukemie: z\u00E1sadn\u00ED zm\u011Bna progn\u00F3zy nemocn\u00FDch po zaveden\u00ED l\u00E9\u010Dby inhibitory tyrozinov\u00FDch kin\u00E1z"@cs .